Biomarkers and Personalised Medicine

Client: University of Cambridge/ Psynova Neurotech with a research programme in biomarkers for neuropsychiatric disorders such as schizophrenia and bipolar disorder.

Ithaka's role:

  • Ithaka appointed by the Cambridge University Proof of Concept Fund to work with scientific founder Dr Sabine Bahn to develop a business plan.
  • Paul Rodgers appointed as Executive Chairman to lead the commercial and fund raising activities.

Results:

Paul has played a significant role in nurturing the Company and in achieving:

  • Over £8M of funding secured from investors, a corporate partner and grants from the Innovative Medicines Initiative and the EU Framework 7 programme;
  • A corporate deal with Rules-Based Medicine Inc. in 2008 which positioned Psynova to: Launch its first product, VeriPsychâ„¢, a diagnostic test for schizophrenia, in USA in 2010;
  • Implementation of a biomarker commercialisation strategy that resulted in an exit for the founders through a trade sale to Myriad Genetics Inc. in 2011;
  • A collaboration with a Hoffman-La Roche to develop a companion diagnostic for a novel schizophrenia drug.

Client: Exploristics Ltd, an emerging biostatistics services company specialising in the simulation, planning and analysis of clinical trials, particularly those involving the use of biomarkers

Ithaka's role:

Ithaka's role:

  • The founder appointed Bill Primrose and Paul Rodgers of Ithaka to assist and mentor him in the development of the business, to identify new commercial opportunities, and support fund-raising efforts to secure investment to create and market innovative new software products.

Results:

  • New clients identified and contracts secured.
  • A fully-costed business plan generated and distributed to Ithaka's investor contacts.
  • Meetings with potential investors conducted.